Research

Extracellular Vesicles (EVs) are nanoparticles released by cells. They carry various bioactive molecules (i.e. proteins, lipids, metabolites, and nucleic acids) needed for cell-to-cell communication. Compared to conventional nanoparticles such as viral and synthetic nanocarriers, endogenously derived EVs can evade phagocytosis, retain high biocompatibility, and exhibit low immunogenicity. More importantly, EVs can be engineered to acquire therapeutic qualities. Given these unique and beneficial characteristics, EVs have recently been the subject of great interest in the field of nanoparticle-based therapeutics.

Recently, we reported that agonist antibody of Thrombopoietin receptor may induce differentiation of killer cells from acute myeloid leukemia(AML). Intriguingly, the antibody-induced killer cells showed cytotoxic activity against cancer cells.In this study, we suggested the possibility of agonist antibodies to change the differentiation state of cancer cells into those that attack and kill other members of the malignant clone from whence they originate. In the future, we would like expend this project to develop efficient strategies to reduce the recurrence of AML.posted 2019-11-04 11:45:37 by ykm3280